17 August 2026 | 6:56AM HKT Equity Research JD Health International (6618.HK) 1H26 review and NDR takeaways: Demonstrating strong execution amid regulation uncertainty; 2H26 set to accelerate; Buy 6618.HK 12m Price Target: HK$59.00 Price: HK$39.50 Upside: 49.4% JD Health reported largely inline 1H26 results and mgmt's refreshed FY26 guidance reiterates our view that JDH is demonstrating strong execution capabilities and further gaining share across segments, despite the nutrition/GLP related regulation unce ...

ab 13 August 2026 Global Research US Healthcare A Look at Today's Stock Movers, News & Key Data What We Thought Was Interesting Today Today's UBS Crowding Data highlights crowding trends for CRO names as of 8/11. The chart compares each ticker's latest crowding factor versus its latest 30-day average. ICLR and FTRE are marginally crowded long; MEDP and IQV are crowded long, while CRL and CERT are marginally crowded short. Investor focus: 1) inbounds on the impact and read-throughs to the group from COR sayi ...